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Abstract
In human glioblastoma multiforme (GBM), RAS activity is upregulated in the majority of the tumors. Furthermore,
the levels of phospho–mitogen-activated protein kinase/extracellular signal regulated kinase (MAPK/ERK), a down-
stream effector of RAS, are also increased. In mice, activated KRas cooperates with the loss of INK4a-ARF locus or
with activated Akt to induce gliomas, confirming an important role for this pathway in glioma biology. However, to
correctly target therapies against the RAS signaling pathway, it is necessary to identify the effectors that contribute
to RAS-mediated gliomagenesis. In this study, we investigated the contribution of RAF signaling in glioma onco-
genesis. We find that the levels of RAF-1 and BRAF proteins and RAF kinase activity are increased in human GBM
samples. We confirm the importance of this finding by demonstrating a causal role for a constitutively active Raf-1
mutant in glioma formation in mice. Specifically, we find that activated Raf-1 cooperates with Arf loss or Akt ac-
tivation to generate gliomas similar to activated KRas under the same conditions. Our study suggests that the
oncogenic effect of KRas in glioma formation may be transduced at least in part through Raf signaling and that
therapeutic targeting of this pathway may be beneficial in glioma treatment.
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Introduction
Glioblastoma multiforme (GBM) is a grade IV astrocytoma as de-
fined by the World Health Organization [1]. It is the most common
and most malignant type of central nervous system tumor, with a
dismal prognosis of about 1 year with extensive resection, chemo-
therapy, and radiotherapy [2]. One of the reasons this tumor is ex-
tremely difficult to treat is its complex biology. Studies of human
GBM samples have uncovered a large number of genetic abnormal-
ities. Among those abnormalities, deregulation of signal transduction
pathways and loss of cell cycle control are prominent [3].
Disruption of cell cycle control in GBMs commonly occurs through
the loss of INK4a-ARF, a locus that encodes two proteins, namely,
p16INK4a and p14ARF, which in turn control the activity of RB and
p53 proteins, respectively. About two-thirds of all human GBMs have
lost the INK4a-ARF locus [3]. Furthermore, those tumors that do re-
tain the wild-type p16INK4a and p14ARF instead display loss of p53 and
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RB, amplification of CDK4 and/or MDM2, other players involved in
cell cycle control [4,5]. Overall, the majority of human GBMs have
lost the ability to regulate cell proliferation [3], underscoring the im-
portance of these genetic abnormalities in tumor formation. Causal
contribution of INK4a-ARF or p53 loss to gliomagenesis was demon-
strated in transgenic mouse models [6–9].
Deregulation of signal transduction pathways is another hallmark
feature of most human GBMs. Specifically, overexpression and/or
gain-of-function mutations in EGFR, PDGFR, and FGFR receptor
tyrosine kinases are frequently observed, leading to the activation of
downstream effectors, such as RAS and PI3K/AKT pathways [10]. Ac-
tivation of AKT is seen in ∼70% of GBMs, and increased RAS pathway
activity is observed in virtually all GBMs [11–13]. Interestingly, al-
though mutations in RAS are frequently observed in other cancer types,
they are not found in GBMs, suggesting that increased RAS activity is
due to upstream factors [3]. The possible importance of RAS-related
signaling to glioma formation is unsurprising, given that RAS is in-
volved in many cellular processes, including proliferation, migration,
differentiation, and apoptosis. Indeed, several mouse models of glioma
have causally implicated activated HRAS and KRAS in glioma forma-
tion [9,14,15]. Extracellular signal–regulated kinase/mitogen-activated
protein kinase (ERK/MAPK) signaling, one of the downstream effectors
of RAS, is also increased in human GBMs [11,13]. However, whether
the oncogenic effect of RAS in gliomagenesis is transduced through the
RAF-ERK signaling remains unknown and needs to be addressed to de-
sign drugs directed against specific molecular targets. The RAF protein
kinases are of particular interest, because they have been shown to be
involved in transformation and tumorigenesis [16].
The RAF family of kinases comprises three members: A-, B-, and
C-RAF/RAF-1. These serine/threonine kinases have a common struc-
ture, with an N-terminal regulatory region and a C-terminal catalytic
domain [17]. The best-described downstream effector of RAF is the
MEK-MAPK/ERK signaling pathway, although there has been recent
speculation about existence of other targets [18]. Mutations in BRAF
have been observed in melanoma, thyroid, colorectal, and ovarian can-
cers, among others [19], and recently, germ line mutations associated
with a form of leukemia were uncovered in RAF-1 [20]. However,
RAF involvement in gliomagenesis is yet to be studied.
We have previously used the RCAS/tv-a system of gene transfer to
somatic cells to show that activated KRas can cooperate with activated
Akt or INK4a-ARF loss to induce gliomas in mice [21,22]. Here, we
sought to determine whether the RAF-MEK-ERK signaling pathway,
one of the downstream effector of KRas, is involved in gliomagenesis.
In this study, we show that the levels of RAF-1 and BRAF proteins and
RAF kinase activity are upregulated in the majority of human GBMs.
Furthermore, we used the RCAS/tv-a system to address the glioma-
genic ability of a constitutively active Raf-1 mutant [23] in glial pro-
genitors. We show that Raf-1 activation cooperates with INK4a-ARF
loss or Akt activation in glioma formation in mice. The Raf-1 tumors
are very similar to those induced by KRas in incidence and histologic
features. These results indicate that RAS contributes to human GBM
formation in part through RAF signaling. Our findings reveal potential
therapeutic targets important to the biology of GBM.
Materials and Methods
DNA Constructs and DF1 Cell Transfection
RCAS-KRasG12D, RCAS-Akt, and RCAS-eGFP have been de-
scribed previously [10]. RCAS-KRas was a gift from Harold Varmus
(Memorial Sloan-Kettering Cancer Center). RCAS-Akt/HA, which
carries the activated form of Akt designated Akt-Myr D11-60 and
has an HA tag sequence added to the 3′-end of the cDNA, was a
gift from Peter Vogt (Scripps Institute, La Jolla, CA). pBABEpuro-
ΔRaf1-22W was kindly provided by C.M. Counter (Duke Univer-
sity, Durham, NC). The ΔRaf1-22W fragment was released with an
EcoRI digest and cloned into pYAP6 cut with EcoRI. After confirm-
ing the correct orientation, a NotI/ClaI fragment was released and
subcloned into RCAS-Y to generate RCAS-ΔRaf1-22W. DF1 pack-
aging cells were obtained from American Type Culture Collection
(ATCC, Manassas, VA) and maintained in ATCC medium (Cat.
#30-2002), supplemented with 10% fetal calf serum in a humidified
atmosphere at 39°C and 5% CO2. Transfections with RCAS plas-
mids were performed as previously described [21].
Generation and Infection of Primary Brain Cultures
Brains of P0 neonatal Ntv-a wt mice were isolated and dissociated
in DMEM medium supplemented with 10% FBS. Following centri-
fugation at 1000g, cells were resuspended in DMEM/10% FBS, plated
on 100-mm tissue culture dishes and maintained in a humidified at-
mosphere at 37°C and 5% CO2. Infection with RCAS viruses was per-
formed as described previously [6]. Briefly, conditioned media from
∼80% confluent DF1 cells transfected with RCAS plasmids were col-
lected, filtered through 0.22-μm filters (Nalgene, Rochester, NY), and
applied to ∼40% to 50% confluent Ntv-a wt glial progenitors. Infec-
tions were repeated four times in 24-hour intervals. RCAS-GFP was
used as an infection control in all experiments.
Human Brain Tissue
All human brain tumor samples were obtained from the Memorial
Sloan-Kettering Cancer Center tissue bank with the approval of the
institutional review board. Normal brain cortex was obtained from
adult human autopsy (Analytical Biological Services, Inc., Wilmington,
DE). The samples were flash frozen in liquid nitrogen immediately
after removal and were stored at −80°C.
Lysate Preparation
Glial progenitors infected with RCAS viruses as above were main-
tained in serum-free medium overnight, washed three times with
ice-cold PBS, harvested, and pelleted. Cold lysis was performed in
mammalian protein extraction reagent (M-PER; Pierce, Rockford,
IL), supplemented with 100 mM NaCl, 30 mM NaF, 1 mM EDTA,
0.5 mM PMSF, 1 mM Na3VO4, and protease inhibitor cocktail
(Roche, Indianapolis, IN), and protein concentrations were determined
using the Bio-Rad Protein Assay Reagent (Bio-Rad, Hercules, CA).
To prepare human tissue lysates, frozen GBM samples and control
normal cortex were ground into powder in liquid nitrogen using a
mortar and pestle. Cold lysis was performed using T-Per (Pierce),
supplemented with 30 mM NaF, 1 mM Na3VO4, 1 mM PMSF,
and inhibitor cocktail (Roche), for 45 minutes with rotation. Cleared
lysates were measured for protein concentration using the Bio-Rad
Protein Assay Reagent (Bio-Rad).
Western Blot Analysis
A total of 100 μg of total protein were resolved on a 10% SDS-
PAGE gel and were transferred to polyvinylidene difluoride mem-
brane (Millipore, Bedford, MA). After blocking with 5% nonfat milk
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in PBS–0.1% Tween-20 (PBST), membranes were incubated over-
night with the following primary antibodies diluted in 5% nonfat
milk in PBST (or 5% BSA in PBST for phospho-specific antibodies):
anti–phospho-Erk1/2ser217/221 (Cell Signaling Technology, Beverly,
MA), 1:1000; anti–Erk1/2 (Cell Signaling Technology), 1:1000; anti–
Raf-1 (sc-133; Santa Cruz Biotechnology, Santa Cruz, CA), 1:200;
anti-Braf (Santa Cruz Biotechnology), 1:200; anti–phospho-Mek1/
2 (Cell Signaling Technology), 1:1000; anti–Mek1/2 (Cell Signaling
Technology), 1:1000; anti–phospho-AktSer473 (Cell Signaling Tech-
nology), 1:1000; anti-Akt (Cell Signaling Technology), 1:1000;
and anti-KRas (Santa Cruz Biotechnology), 1:200. For loading con-
trol, incubation for 1 hour with anti-GAPDH (Advanced Immuno-
Chemical, Long Beach, CA) at 1:1000 or with anti-actin (Santa Cruz
Biotechnology) at 1:500 in 5% nonfat milk in PBSTwas used. Sec-
ondary antibodies were diluted 1:1000 in 5% nonfat milk in PBST.
Secondary peroxidase–conjugated anti-rabbit (Amersham Biosciences,
Piscataway, NJ), anti-goat (Roche), and anti-mouse (Roche) antibodies
were used. Signal was developed using an enhanced chemilumi-
nescence kit (Amersham Biosciences) and was visualized on a film
(BioMax MR; Kodak, Rochester, NY). To probe for multiple anti-
bodies, membranes were stripped using a stripping buffer (Pierce)
according to the manufacturer’s instructions. Incubation using the
appropriate secondary antibody only followed enhanced chemilumi-
nescence was used to determine the completeness of stripping. Mem-
branes were reblocked in 5% nonfat milk in PBST before the new
primary antibodies were applied. For quantification, band density
was determined using ImageJ software and was normalized against
loading control. Statistical analysis was performed with GraphPad
Prism4 software (GraphPad Software Inc., San Diego, CA) using the
two-tailed Student’s t test. P values < .05 were considered significant.
RAF Kinase Assay
Ground frozen GBM samples, normal cortex tissue, and control
cell pellets were lysed at 4°C in buffer A [50 mM Tris–HCl pH
7.5, 100 mM NaCl, 1% Triton X-100, 50 mM NaF, 10 mM
Na3PO4, 5 mM EDTA, 1 mM Na3VO4, 1 mM PMSF, and inhib-
itor cocktail (Roche)] for 45 minutes with rotation. Cleared lysates
were measured for protein concentration, and 100 μg of total pro-
tein was used for the kinase assay. The assay was performed imme-
diately using the Raf kinase activity kit (Cat. #17-357; Upstate
Technologies, Lake Placid, NY) according to the manufacturer’s in-
structions. Briefly, lysates containing 100 μg of total protein were
incubated with recombinant inactive MEK1, inactive ERK2, and
cold ATP. After a 30-minute incubation at 30°C with agitation, 4 μl
of the reaction mixture (Step1) was used for the second step of the
assay. In this step (Step2), 4 μl of Step1 were incubated for 10 minutes
at 30°C with [γ-32P]ATP and recombinant Erk2 substrate myelin
basic protein. The Step2 reactions were spotted onto nitrocellulose
paper and were washed extensively. 32P incorporation was quantified
using a scintillation counter (Perkin-Elmer, Waltham, MA). Astrocytes
expressing activated Raf-1 were used as a positive control, and astro-
cytes expressing eGFP were the negative control. Statistical comparison
was performed with GraphPad Prism4 software (GraphPad Software
Inc.) using the two-tailed Student’s t test. P value < .05 was consid-
ered significant.
RAL Activity Assay
Ground frozen GBM samples and normal cortex tissue were
lysed at 4°C in buffer B (50 mM Tris–HCl pH 7.5, 200 mM NaCl,
1% NP-40, 10 mM MgCl2, and 0.5 mM dithiothreitol). Cleared
lysates were measured for protein concentration, and 800 μg of
total protein was used for the assay. The levels of activated RAL
(RAL-GTP) were measured using GST-RalBP1 agarose beads (Up-
state Technologies) according to the manufacturer’s instructions.
Briefly, the lysates were incubated with the GST-RalBP1 beads for
30 minutes at 4°C with rotation, followed by three washes with
buffer B. Proteins were resolved on a 12.5% SDS-PAGE and were
processed as above. Membranes were incubated overnight with anti-
RalA antibody (BD Transduction Laboratories, San Jose, CA) diluted
1:3000 in 5% nonfat milk in PBST, followed by HRP-conjugated
anti-mouse antibody (Roche) 1:1000 in 5% nonfat milk in PBST
for 1 hour at room temperature, and developed as above. In ad-
dition, 10% of the input lysate was resolved on a 12.5% SDS-
PAGE and processed as above to determine the levels of total RalA
in the samples.
Generation of Tumor-Bearing Mice
All mouse strains used in this study have been described [6,22].
DF1 cells producing the appropriate RCAS viruses were cultured
to ∼80% confluence. Approximately 104 cells in a 1-μl volume were
injected intracranially into the right frontal cortical areas of neonatal
(P0 to P1) mice using a Hamilton syringe. Statistical analysis was
performed with GraphPad Prism4 software (GraphPad Software
Inc.) using the log-rank test applied to Kaplan–Meier graphs.
Brain Sectioning, Hematoxylin and Eosin Staining,
and Immunohistochemistry
Tissue processing, sectioning, and hematoxylin and eosin staining
were performed as described previously [6]. Primary antibodies were
diluted as follows: anti–proliferating cell nuclear antigen (PCNA)
(Oncogene Research Products, Cambridge, MA), 1:100; anti–phospho-
Erk1/2, anti–phospho-AktS473, and phospho-S6RP (Cell Signal-
ing Technology), 1:50; anti–glial fibrillary acidic protein (GFAP)
(MAB3402; Chemicon, Temecula, CA), 1:1000; anti-nestin (BD
Pharmingen, San Jose, CA), 1:200; and anti-p19Arf (SantaCruzBiotech-
nology), 1:200. Sections were incubated overnight at 4°C. The appro-
priate secondary biotinylated antibodes (Vector BioLabs, Philadelphia,
PA) were used at 1:250 for 1 hour at room temperature. All antibodies
were diluted in 5% horse serum PBS–0.05% Tween-20. Peroxidase
signal was developed using the ABC kit (Vector) and visualized using
the DAB substrate (Vector). Control stainings using secondary antibody
only were performed for all antibodies.
Immunocytochemistry
Cells were seeded on glass coverslips and grown to approximately
50% confluence. After fixation with 4% paraformaldehyde for
20 minutes at room temperature, cells were washed three times
with PBS, permeabilized for 10 minutes with PBS/0.5% Triton X-
100, washed again once with PBS, and blocked with PBS/3% BSA
for 30 minutes. Primary anti–nestin rabbit polyclonal antibody (BD
Pharmingen) was applied at 1:500 dilution in PBS/3% BSA over-
night at 4°C. Cells were washed three times with PBS and were in-
cubated with Alexa Fluor 555–conjugated anti-rabbit secondary
antibody (Molecular Probes, Eugene, OR) at 1:300 in PBS/3% BSA
for 1 hour at room temperature. After washing three times with PBS,
cells were counterstained with 4′,6-diamidino-2-phenylindole and
then washed, and the coverslips were mounted using 70% glycerol.
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Results
RAF Activity Is Increased in Human GBMs
Whereas RAS activity and phospho-ERK levels are upregulated in
human GBMs, the activity status of the intermediate members of
this pathway is unknown. We addressed the status of RAF kinases
in these tumors, as they are directly downstream of RAS and are im-
plicated in many cancer types [19]. We analyzed 20 human GBM
specimens, as well as 7 oligodendrogliomas. First, we determined
the total levels of RAF-1 and BRAF proteins in these tumors and
compared them to the normal human brain cortex. The levels of total
RAF-1 and BRAF in the majority of the tumors were significantly
increased in comparison to normal brain tissue (Figure 1, A and
B). We also analyzed the status of AKT and RAL, other effectors
known to be downstream of RAS. We found that levels of phos-
phorylated AKT were upregulated in the majority of the tumors,
      
    
     
Figure 1. RAF activity is increased in human GBMs. (A) RAF signaling pathway in a group of 20 human GBM specimens and 7 human
oligodendrogliomas compared to normal brain cortex (NBC). Actin was used as a loading control. (B) Quantification of RAF protein levels in
(A), *P< .05, **P< .01. (C) Total RAF kinase activity in a subset of the GBMs (n= 7) examined in (A). Normal brain cortex (n= 2) was used
as a negative control. C32 cell line, which has the activating V600E mutation in BRAF, was used as a positive control. The graph represents
the mean ± SD (bars) of at least three independent experiments. *P < .05. (D) Analysis of AKT and RAL activities in human tumors.
Western blot analysis of 20 GBM and 7 oligodendroglioma (ODG) samples shows increased Ser473 phosphorylation of AKT compared
to NBC. Levels of GTP-bound (active) RAL in 7 GBM specimens show a slight decrease in activity compared to two normal cortex samples
(NBC). Levels of total RAL protein were examined using 10% of the input whole-cell lysate (WCL). Actin was used as a loading control.
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underscoring the importance of this pathway in glioma biology [10],
whereas levels of activated RAL (RAL-GTP) were slightly downregu-
lated (Figure 1D). To confirm that our findings were not simply due
to the high proliferation rate of the tumors compared to normal tis-
sue, we compared primary mouse astrocytes synchronized in G0 by
serum starvation to the normally replicating astrocytes. Western blot
analysis showed no differences in either B-Raf or Raf-1 between the
two treatments (data not shown). However, the levels of phospho-
Erk increased slightly in replicating cells, indicating that this signal-
ing cascade may be regulated in part by the cell cycle status (data not
shown). Next, we measured RAF kinase activity to find whether it cor-
related with the increased protein levels. In analyzing 7 GBM samples
(from the above pool of 20), we saw that, although the RAF kinase
activity levels varied between specimens, they were consistently signif-
icantly higher compared to normal tissue (Figure 1C ). This suggested
that the overexpessed RAF kinases were active. The increased kinase
activity was due neither to the commonly observed BRAF V600E mu-
tation [19] nor to any activating RAF-1 mutations as determined by
DNA sequencing (data not shown). These data are in line with a recent
report that analyzed a total of 93 gliomas of various histologic subtypes
and found only two cases of mutation of BRAF, whereas gene copy am-
plification was present in nearly 50% of the tumors analyzed [24]. Of
note, EGFR gene amplification was also frequently seen in the tumors
with amplified BRAF [24]. Both BRAF and EGFR genes are located on
chromosome 7 (7q34 and 7p12, respectively), making their coamplifi-
cation possible when the entire chromosome 7 is gained. Additionally,
array comparative genomic hybridization analysis of 87 GBMs did not
detect gene amplification of RAF-1 (Cameron Brennan, personal com-
munication). Although the exact mechanisms of overexpression are un-
known, it may be mediated by upstream effectors such as activated RAS
and growth factor receptors, which are known to be activated in these
tumors [11,12,25]; increased expression of the RAF proteins provided a
selective advantage to accommodate increased signaling through these
pathways. Overall, the results of the human tumor analysis suggested
the importance of this signaling pathway and prompted us to address
its possible causal role in glioma formation.
Constitutive Activation of Raf-1 Induces Hyperplastic Lesions
in Ntv-a Mice
The RCAS/tv-a system of gene transfer to somatic cells has been
described [26]. We have previously used this system to demonstrate a
causal role for KRas activation in gliomagenesis. Specifically, we
Figure 2. RCAS-Raf1 induces small hyperplastic lesions in Ntv-a wt mice. (A) Glial progenitors were isolated from newborn mouse pups
(P0) and grown in culture as described in the Materials and Methods section. Progenitor status was confirmed by immunofluorescence
staining against nestin (nestin in red and DAPI staining in blue); scale bar, 50 μm. (B) Activities of the viral KRas and Raf-1 mutants were
confirmed by infecting primary Ntv-a glial progenitors with the appropriate RCAS viruses and assaying for Raf-1, phospho-Erk1/2 and
total Erk1/2, and KRas levels. Mutant Raf-1 is indicated with an arrow; molecular size marker is shown to the left. RCAS-GFP was used as
an infection control. GAPDH was used as a loading control. (C) Representative examples of small lesions induced in Ntv-a wt mice. An
hematoxylin and eosin staining illustrates the morphology of a typical Ntv-a wt lesion (original magnifications of second row: left panel,
×100 and right panel, ×200). Immunohistochemical analysis indicates Erk activation, whereas GFAP and nestin stainings suggest glial
character. Proliferation is evidenced by PCNA-positive cells. Scale bar, 50 μm.
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showed that constitutively active KRas can cooperate with a loss of
INK4a-ARF to induce spindle-cell gliomas [8,22] or with activated
Akt to induce GBMs [10,13,21]. Here, we sought to determine
whether activation of Raf-1, one of the downstream effectors of KRas,
similarly contributes to gliomagenesis. In human gliomas, both RAS
and RAF are wild-type, and continuous signaling is mediated by up-
regulation of upstream effectors such as hyperactive epidermal growth
factor receptor (EGFR). In the absence of signaling by these regulators
in our system, we instead used a constitutively active mutant of Raf-1,
ΔRaf1-22W, previously shown to transform NIH 3T3 cells in vitro
[23] and studied its tumorigenic ability compared to the activated
KRas mutant.
We first tested ΔRaf1-22W in vitro to ensure that it was active in
glial progenitors. We generated primary cell cultures derived from
brains of neonatal (P0) Ntv-a mice. These cultures consisted 100%
of tv-a–expressing glial progenitors as confirmed by immunofluores-
cence staining for the neural progenitor marker nestin (Figure 2A).
We next infected these cultures with RCAS-ΔRaf1-22W (hereafter
referred to as RCAS-Raf1), RCAS-KRasG12D, or RCAS-GFP as a
control. RCAS-Raf1 and RCAS-KRasG12D induced phosphorylation
of Erk1/2 to similar levels (Figure 2B), indicating that both con-
structs were active. Interestingly, increased levels of total Erk1/2 were
seen in both RCAS-KRasG12D– and RCAS-Raf1–infected cells com-
pared to RCAS-GFP controls, suggesting the presence of positive feed-
back during the activation of this pathway [27].
Next, we looked at the tumorigenic ability of RCAS-Raf1. We in-
jected neonatal Ntv-a wt mice with DF1 cells producing RCAS-Raf1
or RCAS-KRasG12D (n = 30 for each construct). Animals were mon-
itored for symptoms of glioma formation such as lethargy, poor groom-
ing, weight loss, and hydrocephalus. None of the animals injected with
either RCAS construct became moribund due to glioma formation dur-
ing the duration of the experiment. Therefore, all animals were sacri-
ficed at the 14-week endpoint, and their brains were analyzed for the
presence of any asymptomatic lesions. Whereas none of the wild-type
mice injected with RCAS-KRasG12D showed any brain abnormalities,
in line with our previous data, approximately 30% of the mice injected
with RCAS-Raf1 displayed small hyperplastic lesions in the cortex
(Figure 2C ). These lesions were glial in character, as indicated by GFAP
immunostaining. Furthermore, increased phospho-Erk immunostain-
ing suggested activation of KRas signaling, and PCNA staining indi-
cated that the lesions were proliferating (Figure 2C ). However, the
lesions did not progress to fully developed gliomas, confirming that
Figure 3. Raf-1 activation induces gliomas in Ntv-a;Arf−/− mice. (A) A representative KRas-induced glioma (i, left) and Raf-1–induced
glioma (i, right) in Ntv-a;Arf−/− background. A higher magnification reveals spindle-cell sarcoma-like morphology, with microvascular
proliferation (ii, microvasculature indicated with blue arrowheads), giant cells (iii, black arrowheads), and pseudopalisading necrosis
(iv, asterisk). Scale bar, 50 μm. (B) Examples of gliomas induced with RCAS-Raf1 in different parts of the brain in Ntv-a;Arf−/− back-
ground. (C) Kaplan–Meier analysis comparing KRas- and Raf-1–induced tumors in Ntv-a;Arf−/− mice. P = .28 (ns).
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activation of MAPK signaling alone is insufficient for glioma forma-
tion. To study the possibility that the 14-week time period was not
long enough to allow these lesions to progress further, we extended
the experiment to 6 months for a subset of Ntv-a wt RCAS-Raf1–
injected animals but did not observe additional tumor progression
(data not shown). We also explored the possible loss of p19Arf as a
contributing factor in the formation of the lesions. Immunohisto-
chemical staining for p19Arf showed presence of Arf-positive cells
(data not shown), suggesting that Arf loss was likely not the causal
event during initiation of lesion formation.
Raf-1 Activation Cooperates With Arf Loss in
Glioma Formation
To investigate whether KRasG12D and Raf-1 are similarly able to
cooperate with Arf loss to induce gliomas, we injected Ntv-a;Arf −/−
animals with RCAS-KRasG12D– or RCAS-Raf1–producing DF1 cells
(n = 24 and 26, respectively). As discussed earlier, RCAS-KRasG12D
induced high-grade gliomas in Ntv-a;Arf −/− mice, with spindle-cell
morphology, occasional pseudopalisading necrosis, and extensive mi-
crovascular proliferation (Figure 3A). Similarly, RCAS-Raf1 induced
high-grade gliomas in Ntv-a;Arf −/− animals, with histologic features
similar to KRas-induced tumors (Figure 3, A and B). In particular,
both tumor types were polymorphic, with the presence of spindle
cells and cells with more astrocytic character, with a considerable
overlap of features. They were both characterized by large numbers
of giant cells, occasional presence of gemistocytes, fascicular cell
growth, and endothelial proliferation. The overall incidence of glio-
mas induced with KRas and Raf-1 was also similar, 69.6% and
65.4%, respectively, although the tumor latency was somewhat
shorter in KRas tumors (Figure 3C ). The increased latency in Raf-1
tumors could be due to the fact that KRas has other known down-
stream effects in addition to the Raf-Erk signaling cascade that could
enhance tumor initiation [28] or because of different levels of expres-
sion of RCAS-KRasG12D and RCAS-Raf1.
We also compared the immunohistochemical characteristics of
KRas and Raf-1 gliomas by analyzing 10 tumors of each type. Inter-
estingly, although both KRas and Raf-1 tumors stained highly for
phospho-Erk, indicating activation of this pathway, the pattern of
phospho-Erk staining in KRas tumors was patchy (approximately
30% of the total tumor area), whereas Raf-1 tumors stained more
homogeneously throughout (Figure 4A). This again indicates that,
whereas Raf-1–Erk signaling cascade contributes to KRas-induced
gliomagenesis, it may not be the only critical pathway activated by
KRas. In support of this, KRas gliomas also had low but detectable
levels of phospho-Akt (Ser473), whereas Raf-1 tumors had no detect-
able phospho-Akt (Figure 4B). Thus, whereas the KRas– and Raf-1–
induced gliomas could be described to be in the same continuum,
they were not identical, confirming that although the oncogenic ef-
fect of KRas may be transduced largely through Raf-1 signaling in
the context of Arf loss, other signaling pathways such as PI3K-Akt
may also play a role in tumor formation, accounting for the different
growth rates of the two tumor types. Both tumors had glial character,
as evidenced by GFAP and nestin immunostaining, and were highly
proliferative, as shown by PCNA immunohistochemistry (Figure 4,
C and D).
Figure 4. Immunohistochemical comparison of KRas- and Raf-1–induced tumors in Ntv-a;Arf−/− mice. Representative immunohisto-
chemical patterns of each tumor type are illustrated. Note patchy phospho-Erk staining in KRas glioma versus a more homogeneous
staining pattern in Raf-1 glioma (A); scale bar, 50 μm.
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Raf-1 Activation Cooperates with Akt Activation in
GBM Formation
We previously demonstrated cooperation between KRas and Akt
activation in GBM formation in Ntv-a wt mice [10,13,21]. Those
tumors were highly similar to human GBMs in that they demon-
strated microvascular proliferation, pseudopalisading necrosis, and
nuclear atypia—the hallmark features of human GBMs (Figure 5A).
To investigate whether Raf-1 activation can also cooperate with activa-
tion of Akt, we injected Ntv-a wt mice with DF1 cells producing
RCAS-Raf1 (n = 15), or with a combination of DF1 cells producing
RCAS-Raf1 and RCAS-Akt (n = 25). Whereas Raf-1 alone induced
only small hyperplastic lesions in approximately 30% of the mice as
discussed in the above paragraphs, a combination of Raf-1 and Akt
was able to initiate formation of parenchymal tumors in 52% (13 of
25) of the mice. Of those 13 tumors, 4 presented as small lesions
(<5% of the parenchyma), 5 were medium-sized (5% to 30% of
the parenchyma), and 3 were large (>30% of the parenchyma)
(Figure 5C ). These tumors had the characteristics of GBMs and were
very similar to the KRas+Akt–induced gliomas (Figure 5, A and B).
Immunohistochemical analysis of the tumors showed glial character
as indicated by GFAP and nestin staining. They were highly prolif-
erative, as evidenced by PCNA staining. High levels of phospho-Erk
indicated an increase in MAPK signaling; phospho-Akt and phospho-
S6RP were evidence of increased Akt–mammalian target of rapamycin
pathway signaling (Figure 5B). Overall, the immunohistochemical fea-
tures of Raf-1+Akt tumors were similar to both KRas+Akt gliomas and
to human GBMs [10]. These data confirmed cooperation between
Raf-1 and Akt activation in glioma formation. Importantly, the tumor
latency for the Raf-1+Akt GBMs was longer than that for KRas+Akt
tumors [10,18]; this again suggests that, although Raf-MAPK signal-
ing plays an important role in KRas-induced gliomagenesis, this path-
way is not solely responsible for tumor formation.
Discussion
Glioblastoma multiforme is a complex disease, with a multitude of
genetic aberrations already uncovered, and likely more still to come.
In particular, multiple signaling pathways downstream of growth fac-
tor receptor tyrosine kinases such as EGFR and PDGFR are upregu-
lated in the majority of GBMs. Therefore, the design of effective
mechanism-based drugs depends on the ability to tease apart abnor-
malities that are causal to tumor formation from those that are sec-
ondary events. We previously demonstrated that oncogenic signaling
by KRas in cooperation with the loss of Arf tumor suppressor or ac-
tivation of Akt can generate gliomas in mice [8,21,22]. In the present
study, we were able to investigate this pathway further and show that,
under the same genetic conditions, activated Raf-1 and activated
KRas have a similar gliomagenic effect.
Constitutive activation of the RAS-MAPK signaling pathway is a
common event in many human cancers that can occur as a result of
either abnormal activation of growth factor receptor tyrosine kinases
such as EGFR or upregulation of RAS or RAF activity [29]. BRAF
Figure 5. Activated Raf-1 cooperates with activated Akt to induce GBMs in Ntv-a wt mice. (A) Histologic comparison of KRas+Akt (left)
and Raf-1+Akt GBMs (right). Tumors display the hallmark characteristics of human GBMs: pseudopalisading necrosis (ii, asterisks),
giant cells (iii, black arrowheads), and microvascular proliferation (iv, blue arrowheads). Scale bars, 20 (iii) and 50 μm (ii and iv). (B)
Representative immunohistochemical analysis of Ntv-a wt Raf-1+Akt GBM. Scale bar, 50 μm. (C) Analysis of the tumor size in Raf-1
+Akt–driven gliomas (n = 13 tumors) compared to Raf-1 alone (n = 5 tumors).
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mutations have been identified in a variety of cancers, most promi-
nently in melanoma, thyroid, and colorectal tumors [16,19]. Most of
those mutations are found in the catalytic domain of the protein and
lead to an increase in the kinase activity [30,31]. Interestingly, studies
have shown that mutations in RAS and BRAF are normally mutually
exclusive; that is, they do not co-occur in the same tumor [32]. These
findings indicate that activation of this pathway is crucially important
to the tumor biology and furthermore, that the critical oncogenic ef-
fects of RAS are transduced through RAF activity [32,33]. Among
the three RAF isoforms (ARAF, BRAF, and CRAF/RAF-1), BRAF
has long been considered the one predominantly involved in onco-
genic transformation [34,35], mostly because ARAF or RAF-1 muta-
tions had not been found. However, recent studies have identified
two separate germ line mutations in RAF-1 that were associated with
a form of acute myeloid leukemia [20]. Additionally, overexpression
of RAF-1 has been shown to play a role in pulmonary adenocarci-
noma biology [36]. Here, we show that RAF signaling plays an im-
portant role in gliomagenesis, despite apparent absence of genetic
abnormalities in the BRAF and RAF-1 genes [37,38]. Specifically,
Raf-1 activation cooperates with the loss of Arf tumor suppressor
and/or Akt activation to induce gliomas of varying grades in mice.
These findings are significant because these are the genetic alterations
frequently seen in human GBMs. Our data are also supported by a
finding that a small-molecule inhibitor of RAF was able to block the
growth of malignant glioma cell lines in vitro, as well as in a xenograft
model of glioma [39]. Interestingly, our experiments suggest that
tumor initiation and progression may be governed by separate mecha-
nisms, as activated Raf-1 (but not activated KRas) was able to induce
small lesions in ∼30% of the wild-type mice. Conversely, KRas was
more efficient in promoting tumor growth, whereas Raf-induced gli-
omas had a longer latency in the Arf −/− background. There are sev-
eral reasons for this phenomenon. One is that other KRas effectors,
such as PI3K-Akt, play a role in tumor growth and, because these
signals are absent in Raf-1–induced tumors, tumor progression is
delayed. Additionally, there may be regulatory mechanisms that gov-
ern signal transduction from KRas to Raf-1 that are ineffective when
Raf-1 is constitutively activated, thus leading to the formation of
hyperplastic lesions. Finally, these studies confirm that activation of
the KRas signaling pathway alone is insufficient to initiate malignant
glioma formation and requires the presence of other genetic altera-
tions, such as INK4a-ARF deficiency. Altogether, these findings have
important implications for therapeutic strategies.
Any hope of improving the dismal prognosis of GBM patients is
dependent on the ability to correctly identify and target molecular
signaling events important for the continued tumor survival and
maintenance. Presumably, therapeutics directed against tumor-specific
molecular events should achieve that goal while also lessening the
general side effects associated with conventional chemotherapy.
RAS-MAPK signaling pathway is involved in a multitude of cellular
processes, including proliferation, migration, and survival [34,40].
Therefore, taken together with findings by us and by others, it is rea-
sonable to predict that therapeutic inhibition of this pathway might
be an effective component in GBM treatment strategy. Currently,
there are many compounds targeting the various components of
the RAS-MAPK signaling cascade in various phases of clinical trials;
those include inhibitors of RAS itself, as well as RAF and MEK in-
hibitors [34,35,41]. Several of these are also being tested for their
efficacy against glioma. Based on the apparent causal role of RAF
in gliomagenesis, small-molecule inhibitors of RAF may affect tumor
growth. Furthermore, if RAF acts primarily through MEK and
MAPK, MEK inhibitors may also be effective. However, two impor-
tant points must be considered. First, a study examining the sensitiv-
ity of melanoma to MEK inhibition determined that only cells
harboring a mutation in BRAF were susceptible to the drug [42].
It is unknown whether GBMs, which have wild-type RAF genes,
would respond to this treatment. Secondly, although the MAPK
signaling cascade is the most well described pathway of RAF, other
MAPK-independent downstream effectors have been implicated in
recent years, including components of apoptosis/survival pathways
[43,44]. Interestingly, the survival-promoting functions of RAF-1
may not require its kinase activity, with the protein instead acting
as a scaffold for other protein assembly [28,44]. Furthermore, there
is some evidence of BRAF/RAF-1 heterodimerization, by which
BRAF can apparently induce RAF-1 activation; BRAF kinase activ-
ity does not appear to be required for this function [40,45]. These
mechanisms will be further deciphered through preclinical trials of
specific small-molecule inhibitors, elucidating the detailed role of
the RAF signaling pathway in GBM biology.
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